Rajiv Amin

Operates as a late-stage biopharmaceutical company focused on developing transformative therapies for central nervous system disorders

Functions as a College/University

Functions as a College/University

Develops, manufactures and markets pharmaceutical products

Develops, manufactures, and markets medical products and technologies

Kyowa Kirin, Inc. is a specialty pharmaceutical company dedicated to developing specialty medicines primarily for rare, serious, and underserved diseases. The company is based in Bedminster, NJ. The company focuses on therapeutic areas including bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, nephrology, oncology, immunology, allergy, and neurology. Kyowa Kirin advances modalities such as next-generation antibody therapeutics, hematopoietic stem cell gene therapies, cell therapies, and proprietary antibody technologies. The company operates a network with subsidiaries and research facilities across multiple regions and is expanding manufacturing capacity to support late-stage biologic therapies. Kyowa Kirin emphasizes quality assurance, compliance, and patient safety throughout drug development, clinical trials, manufacturing, and commercialization. The company's clinical research prioritizes diversity and transparency, and they support patient communities and advocacy groups through research and educational initiatives. Partnerships with academic institutions, biotech, pharmaceutical companies, and patient organizations are central to their strategy. The company's portfolio includes medicines such as Crysvita, Poteligeo, Nourianz, and Komzifti, supported by patient assistance programs and expanded access policies.